<DOC>
	<DOCNO>NCT01182883</DOCNO>
	<brief_summary>Background : - IMC-A12 experimental substance design inhibit protein call Type I Insulin-Like Growth Factor Receptor ( IGF-1R ) , find cancer cell promote cancer growth . Temsirolimus drug U.S. Food Drug Administration approve treat advance renal cell carcinoma adult . Researchers know combination IMC-A12 temsirolimus work child , want determine whether two drug may effective treatment recurrent tumor . Objectives : - To determine safety effectiveness IMC-A12 temsirolimus treat child adolescent solid tumor . - To determine possible side effect combination IMC-A12 temsirolimus . Eligibility : - Children adolescents 12 month 21 year age solid tumor respond relapsed standard treatment . Design : - Participants screen medical history , physical examination , image study . - Participants receive IMC-A12 temsirolimus 28-day cycle treatment . IMC-A12 give infusion 1 hour , week , 4 week . Temsirolimus also give IMC-A12 30 minute , week , 4 week . - Participants may continue receive IMC-A12 temsirolimus 2 year unless serious side effect develop treatment stop effective . - Participants additional physical exam , blood urine test , image study regularly treatment cycle . - Participants follow regular interval end study collect tumor response progression data ... .</brief_summary>
	<brief_title>A Phase I Study IMC-A12 Combination With Temsirolimus Pediatric Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>Background - IMC-A12 fully recombinant IgG1monoclonal antibody insulin-like growth factor receptor ( IGFR ) . It act antagonist IGF-1 IGF-2 ligand bind block ligand bind IGF-1R inhibits downstream signal two major insulin-like growth factor pathway : MAPK PI3K/AKT . - Temsirolimus small molecule inhibitor mTOR , like rapamycin everolimus form complex FK506-binding protein ( FKBP ) 12 mTOR , inhibit mTOR lead anti-proliferative effect , include G1 phase cell cycle arrest apoptosis . - Inhibition mTOR signal lead upregulation IGF-1R signal lead activation PI3K/AKT/mTOR pathway . Pediatric pre-clinical model demonstrate synergistic anti-tumor effect combine IGF-1R antibody mTOR inhibitor . Objectives - To determine maximum tolerate dose ( MTD ) recommend Phase II dose IMC-A12 ( anti-insulin growth factor-1 receptor monoclonal antibody ) administer intravenous infusion weekly combination temsirolimus administer intravenously weekly child refractory solid tumor . - To define toxicity combination regimen characterize pharmacokinetics IMC-A12 combination temsirolimus patient population . - Secondary objective include define preliminary fashion antitumor activity , assess biologic activity IMC-A12 temsirolimus assess incidence IGFR expression mTOR pathway activation recurrent refractory solid tumor childhood . Eligibility - Patients &gt; 12 month less equal 21 year age diagnosis histologic verification ( except patient intrinsic brain stem tumor , optic pathway glioma pineal tumor elevation serum CSF alpha-fetoprotein beta-HCG ) measureable evaluable relapsed refractory solid tumor . Current disease state must one know curative therapy , therapy proven prolong survival . - Must fully recover acute toxic effect prior therapy , complete within specify prior time frame . - Have adequate organ function determine laboratory evaluation include normal random fast blood glucose within upper normal limit age grade &lt; 2 serum cholesterol triglyceride level . - Subjects uncontrolled infection , know type I type II diabetes mellitus , know bone marrow involvement receive prior monoclonal antibody therapy target IGF-1R temsirolimus eligible . Design - This phase I study IMC-A12 administer every 7 day 1-hour intravenous infusion start dose 6 mg/kg . Temsirolimus administer intravenously 30 minute immediately IMC-A12 weekly schedule , start dose 15 mg/m ( 2 ) . - One cycle therapy consider 28 day . Therapy may continue 2 year absence progressive disease unacceptable toxicity . - All patient require trough blood sample pharmacokinetic analysis IMC-A12 temsirolimus immunogenicity study collect time select routine safety lab . Optional participation additional pharmacokinetic study correlative biology study offer .</detailed_description>
	<mesh_term>Brain Stem Neoplasms</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Eligibility Patients &gt; 12 month less equal 21 year age diagnosis histologic verification ( except patient intrinsic brain stem tumor , optic pathway glioma pineal tumor elevation serum CSF alphafetoprotein betaHCG ) measureable evaluable relapse refractory solid tumor . Current disease state must one know curative therapy , therapy proven prolong survival . Must fully recover acute toxic effect prior therapy , complete within specify prior time frame . Have adequate organ function determine laboratory evaluation include normal random fast blood glucose within upper normal limit age grade &lt; 2 serum cholesterol triglyceride level . Subjects uncontrolled infection , know type I type II diabetes mellitus , know bone marrow involvement receive prior monoclonal antibody therapy target IGF1R temsirolimus eligible .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 4, 2012</verification_date>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Antitumor Activity</keyword>
	<keyword>Biologic Activity</keyword>
</DOC>